Mechanism of Action
PPAR-delta (peroxisome proliferator-activated receptor delta) agonist. Activates genes involved in fatty acid oxidation and glucose homeostasis. Demonstrated endurance enhancement and fat oxidation in animal studies. Development halted when 2-year animal carcinogenicity studies showed accelerated tumor growth in multiple organs at all dose levels tested.
Ester Profile
Non-steroidal oral compound. No ester.
How It's Used in Fitness
Clinical development of Cardarine was permanently abandoned after animal carcinogenicity studies demonstrated accelerated tumor development at every dose tested across multiple organ systems. There is no safe or established performance use case. The endurance and fat oxidation effects that attracted performance interest are real at a mechanistic level. The cancer risk documented in the only comprehensive safety studies ever conducted on the compound makes any use case context inappropriate to present as a legitimate application.
Stacking Context
Cardarine does not have a responsible stacking context. In practice it appears in stacks with SARMs and traditional anabolics for the endurance and lipid management effects. This does not make those combinations appropriate. It makes them stacks that include a compound with documented cancer risk in animal models at all tested doses. The absence of a rational stacking recommendation here is intentional.
Medical Use
- No medical use — development permanently abandoned
- GlaxoSmithKline discontinued all research in 2007 due to cancer findings
- No approved human trials completed
Side Effects
- Cancer development — documented in animals at all tested doses
- Long-term human safety completely unknown
- No human clinical trial safety data available
- Potential for proliferation of existing pre-cancerous cells
What Actually Goes Wrong
GlaxoSmithKline permanently abandoned Cardarine development after two-year carcinogenicity studies showed accelerated tumor development across multiple organ systems at every dose tested in every animal model studied. There is no safe dose established, no long-term human data, and no approved use. The performance community continues to use this compound, representing an acceptance of unknown cancer risk that is not comparable to the risk profile of any other compound on this list. The fact that short-term use has not produced documented cancer cases in humans does not establish safety. It establishes only that the observation period has been short.
Detection Window
WADA detection window of 40+ days. Specific metabolite testing available.
Cardarine is the one compound on this list where the available evidence is not a risk to weigh against a benefit. It is a risk against an athletic advantage that can be achieved through other means. The animal data is not preliminary, it is conclusive enough that a major pharmaceutical company with significant financial investment in the compound decided the risk profile made human development impossible. That decision was made by people with full access to the data and no interest in being conservative. That context matters.